For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Selected for Dow Jones Sustainability Asia Pacific Index for Sixth Consecutive Year

Tokyo, Japan (September 16, 2015) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that for the sixth consecutive year it has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which is one of the world leading indices for Socially Responsible Investment (SRI)*.

 

DJSI are the global indices from S&P Dow Jones Indices LLC of the USA and RobecoSAM AG of Switzerland which assess and select leading, sustainability-driven companies worldwide in terms of economic, environmental and social performance. These are an important investment standard for investors who have an interest in corporate social responsibility (CSR). The DJSI Asia Pacific has selected the top 145 regional sustainability leaders, 6 countries and 46 industries, including 62 Japanese companies out of 600 leading companies, from developed markets in Asia Pacific.

 

In addition to the DJSI Asia Pacific, Daiichi Sankyo has also been included in the FTSE4Good Index, which is also a global SRI index, for the seventh consecutive year.

 

As a company trusted by stakeholders who have a vested interest in its sustained growth and success, Daiichi Sankyo will continue to make every effort to fulfill our social responsibility, to improve the corporate value sustainably and to put into practice its mission, which is, “To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.”

 

* An investment based on criteria that assess a company’s social responsibility performance from social, ethical and environmental perspectives, in addition to financial analysis